In markets like biosimilars, price erosion is a constant reality. Success requires a continuous pipeline of new product launches each year. These launches provide the necessary revenue "lift" to counteract the natural deflation of existing products in the portfolio, ensuring sustained growth and market leadership.
Rather than lobbying regulatory bodies and policymakers as a single entity, Biocon gains influence by actively participating in industry-wide associations like the Biosimilar Forum and Medicines for Europe. This collective approach creates a unified voice for the industry, allowing manufacturers to effectively shape policy and promote a "biosimilar first" strategy.
In the biosimilars industry, where prices inevitably decline over time, full vertical integration (from R&D to commercialization) is essential for survival. By controlling the entire value chain, companies like Biocon avoid profit-sharing with partners, preserving margins and enabling them to withstand market pressures that would cripple less integrated competitors.
With costs of $50-$150 million to bring a single biosimilar to market, the industry has significant barriers to entry. This financial reality will drive consolidation over the next 3-5 years, as smaller, single-product companies (or "one-hit wonders") will struggle to compete with scaled, well-capitalized players like Biocon that possess a robust and diverse product pipeline.
Instead of building new sales teams for each product, Biocon maintains highly trained, specialized commercial teams focused on four core therapeutic areas: oncology, ophthalmology, immunology, and diabetes. This allows the company to efficiently launch new products within these pillars, leveraging existing expertise and infrastructure for scalable and repeatable commercial success.
Biocon strategically uses its stable, cash-generating generics business to finance the capital-intensive development and scaling of its high-growth biosimilar platform. This creates a self-sustaining financial model where the mature business fuels the emerging one, enabling reinvestment into R&D and manufacturing without heavy reliance on external capital.